.Attributes Medication, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of clients with HER2+ state-of-the-art bosom cancer as well as active or even stable mind metastases presented consistent intracranial task and systemic effectiveness of T-DXd.